Galectin-3 expression in macrophages is signaled by Ras/MAP kinase pathway and up-regulated by modified lipoproteins  by Kim, Koanhoi et al.
www.bba-direct.com
Biochimica et Biophysica Acta 1641 (2003) 13–23Galectin-3 expression in macrophages is signaled by Ras/MAP kinase
pathway and up-regulated by modified lipoproteins
Koanhoi Kim1, Eugene P. Mayera, Maurice Nachtigala,*
aDepartment of Pathology and Microbiology, University of South Carolina-School of Medicine, Columbia, SC 29208, USAReceived 3 February 2003; received in revised form 24 March 2003; accepted 28 March 2003Abstract
To study the signaling pathway involved in the regulation of galectin-3 expression we used phorbol ester to stimulate macrophage
differentiation of THP-1 cells. Treatment with phorbol 12-myristate 13-acetate (PMA) increased significantly the level of expression of
galectin-3 in THP-1 cells. PMA-induced galectin-3 overexpression was blocked by: protein kinase C inhibitors staurosporine, calphostin
C, and apigenin; tyrosine-specific protein kinase inhibitors genistein and tyrphostin A25; PD 98059, a selective inhibitor of mitogen-
activated protein kinase (MAPK) kinase 1 (MEK1 or MKK1); and SB 203580, a specific inhibitor of p38 MAPK. Galectin-3 up-
regulation was not affected by exposure to two inhibitors of cAMP-dependent protein kinase (PKA), H-89 and KT5720. Co-transfection
of pPG3.5, a plasmid vector containing the rabbit galectin-3 promoter and the constructs pMCL-MKK1 N3 or pRC-RSV-MKK3Glu that
constitutively express MKK1 and MKK3, raised the activity of galectin-3 promoter by 185% and 110%, respectively. Co-transfection
with a Ha-Ras expression vector stimulated galectin-3 promoter activity approximately 10-fold. Expression of c-Jun or v-Jun raised the
level of galectin-3 promoter activity more the three- and fourfold, respectively. Co-transfection of c-Jun and pPG3.5 5V-upstream deletion
mutants resulted in a reduction of the galectin-3 promoter activity by 50% to 80%. Transfection of c-Jun, v-Jun or Ha-Ras increased
significantly galectin-3 protein in THP-1 cells. These findings indicated that Ras/MEKK1/MKK1-dependent/AP-1 signal transduction
pathway plays an important role in the expression of galectin-3 in PMA-stimulated macrophages. We further investigated the effect of
modified lipoproteins on galectin-3 expression in macrophages. Murine resident peritoneal macrophages loaded with acetylated low-
density lipoprotein (AcLDL) or oxidized LDL (OxLDL) showed increased galectin-3 protein and mRNA. These results showed that
treatment of macrophages with PMA or modified lipoproteins results in galectin-3 overexpression. These findings may explain the
enhanced expression of galectin-3 in atherosclerotic foam cells and suggest that Ras/MAPK signal transduction pathway is involved in
controlling this gene.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Galectin-3; Ras; Jun; MAP kinase; Lipoprotein; Protein kinase
1. Introduction or when stimulated with phorbol esters [7,8] but was lowerIdentified first as an antigen on the surface of murine
thioglycollate-elicited peritoneal macrophages [1], galectin-
3 was later recognized as a member of a h-galactoside-
binding lectin family [2] which is expressed in most macro-
phage populations, macrophage cell lines, interdigitating
dendritic cells and in various lymphoid organs [3–5]. The
level of galectin-3 increased dramatically as monocytes
differentiated into macrophages upon culturing in vitro [6]0167-4889/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
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oplasma gondii or both, or with interferon-g [6].
Galectin-3 expression seems to be controlled by various
stimuli but the signaling pathways are not well studied.
Serum stimulation of quiescent fibroblasts resulted in an
increased level of galectin-3 mRNA as well as protein [9]
and this response may be accounted by several serum
responsive activation regions identified in the human galec-
tin-3 promoter [10]. Infection and transformation with
Kirsten murine sarcoma virus [9], human T lymphotropic
virus-1 (HTLV-1) [11] or human immunodeficiency virus
(HIV) type 1 [12] increased significantly the level of
galectin-3. The activity of the galectin-3 promoter was
significantly up-regulated by expression vectors encoding
the HTLV-1 Tax transactivator protein [11], the Ras onco-ed.
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with phorbol 12-myristate 13-acetate (PMA), but was down-
regulated upon transfection with wild-type p53 [13].
The increased galectin-3 expression seen after treatment
with phorbol esters [7,8] prompted us to use the model of
macrophage differentiation in which PMA acts as a sub-
stitute for diacylglycerol and activates PKC and other
components of the signaling pathway [15,16]. This model
enabled us to investigate the role played by these compo-
nents in galectin-3 regulation. In previous studies we have
found an increase in galectin-3 transcripts in foam cells
isolated from carrageenan-induced granulomas in hyper-
cholesterolemic rabbits [17] and detected expression of
galectin-3 in human atherosclerotic lesions where most of
the foam cells showed this protein [18]. An accumulation of
galectin-3 in the foamy macrophages from myocarditis
lesions developing in Coxsackie virus-infected hypercho-
lesterolemic mice was also reported [19]. Based on these
findings suggesting an association between lipid loading
and overexpression of galectin-3, we have tested the
hypothesis that modified lipoproteins may up-regulate the
expression of galectin-3 as they do for other molecules that
are significant in atherogenesis [20–24]. Our results indi-
cate that components of the Ras-dependent signal trans-
duction pathways control the expression of galectin-3 in
PMA-stimulated macrophages, and modified lipoproteins
induce galectin-3 overexpression in these cells.2. Materials and methods
2.1. Cell cultures and reagents
THP-1 (ATCC TIB 202) and RAW264.7 (ATCC TIB 71)
cells were obtained from the American Type Culture Col-
lection (Rockville, MD) and maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum
(FBS). PMA was purchased from Sigma (St. Louis, MO).
Calphostin C, chelerythrine, genistein, KT5720, H-89, api-
genin, PD 098059, SB 203580, tyrphostin A25, tyrphostin
A1, and staurosporine were purchased from Calbiochem (La
Jolla, CA). Acetylated low-density lipoprotein (AcLDL),
oxidized LDL (OxLDL), and lipoprotein-deficient serum
(LPDS) were purchased from Biomedical Technologies
(Stoughton, MA). Acetylated bovine serum albumin
(AcBSA) was purchased from Gibco-BRL.
2.2. Isolation and lipid loading of peritoneal macrophage
Resident mouse peritoneal macrophages were obtained
from 4–6-week-old C3H/HeN mice by injecting 5 ml of
RPMI-1640 medium with a 26-gauge needle and collecting
the medium with a 18-gauge needle. The isolated cells were
plated onto tissue culture dishes (5106 cells/60-mm dish)
or seeded on cover slips (2.5105 cells/2222 mm). The
cells were cultured in RPMI 1640 medium for 2 h in a 5%CO2 incubator at 37 jC to allow macrophages to adhere.
Nonadherent cells were removed by washing three times
with phosphate buffered saline (PBS). The washed cells
were maintained in RPMI 1640 medium supplemented with
4% LPDS. Resident mouse peritoneal macrophages were
loaded with lipid by incubation with AcLDL or OxLDL. As
negative controls, macrophages were cultured in medium
alone or in medium supplemented with LPDS or AcBSA.
The final concentration of AcLDL, OxLDL, and AcBSA
was 50 Ag protein/ml medium.
2.3. Plasmids and transfections
pPG3.5 is a construct into which the 4.5-kb promoter
region of rabbit galectin-3 was inserted upstream of the
luciferase gene in the promoterless plasmid pMCS-Luc
[13]. The c-Jun expression plasmid (pRSV-c-Jun) contains
the complete mouse c-Jun cDNA and the LTR sequence of
Rous sarcoma virus [25]. The v-Jun expression vector was
constructed by inserting the complete v-Jun sequence down-
stream of the SV40 promoter region [26]. pRSV-r161 is a
construct in which a synthetic c-Ha-Ras with leucine at
position 61 of p21 was inserted in pRSV-neo [27]. Plasmid
pMCL-MKK1 N3 contains a deletion in the residues 32 to 51
of MKK1 that resulted in a mutant with basal activity 45
times greater than that of the wild-type enzyme [28]. Plasmid
pRC-RSV-MKK3Glu containing dominant-active MKK3
was generated by replacement of Ser189 and Thr193 with
glutamic acid. MKK3(Glu) causes selective constitutive p38
MAPK activation [29]. pCMVhan expression plasmid for h-
galactosidase was obtained from Clontech (Palo Alto, CA).
Cells were plated onto 60-mm tissue culture plates at 60%
confluence and transfected by the calcium phosphate pre-
cipitate procedure. For each transfection 1 Ag of pCMVh
was mixed with 3 Ag of pPG3.5 and 3 Ag either of pRSV-neo,
pSV-v-Jun, pRSV-c-Jun, pRSV-r161, pMCL-MKK1 N3, or
pRC-RSV-MKK3Glu, for a total of 7 Ag of DNA per tissue
culture plate. The cells were incubated with the DNA-
calcium phosphate precipitate for 8 h and shocked with cold
20% dimethyl sulfoxide (DMSO) solution in PBS for 3.5
min. After washing three times with cold PBS, the cells were
maintained in Dulbecco Modified Eagle’s Medium (DMEM)
supplemented with 10% FBS. After 48 h, the luciferase
activity was determined using the Luciferase Assay System
(Promega, Madison, WI). Activation of the galectin-3 pro-
moter was calculated by measuring the luciferase activity
normalized to h-galactosidase activity as described [30].
2.4. Nile red staining
Macrophages were washed twice with PBS and fixed
with cold 2% paraformaldehyde for 5 min at room temper-
ature. The fixed cells were washed three times with cold
PBS. Ten microliters of Nile red stock solution (0.5 mg/ml
DMSO) was added to fixed cells in 1 ml of PBS. After
incubation for 5 min at room temperature, stained cells were
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with a Bio-Rad MRC1000 laser scanning confocal micro-
scope (Bio-Rad Microsciences, Wetford, UK). When
stained with Nile red, phospholipids and other amphipathic
lipids give red fluorescence while neutral lipids give yellow
fluorescence [31].
2.5. Immunofluorescent staining of galectin-3
Macrophages grown on coverslips were washed three
times with PBS and fixed with cold methanol (20 jC) for
15 min at 4 jC. After washing three times with PBS, cells
were incubated at room temperature for 50 min with the
anti-galectin-3 monoclonal antibody M3/38. The M3/38
monoclonal antibody was prepared from the supernatant
of the M3/38.1.2.8.HL.2 rat hybridoma (ATCC TIB 166,
American Type Culture Collection). The primary antibody
was removed by washing three times with PBS. The cells
were incubated at room temperature for 30 min with
fluorescein isothiocyanate (FITC)-conjugated anti-rat IgG
(Vector Laboratories, Burlingame, CA) diluted 1:100 with
PBS containing 3 mg bovine serum albumin (BSA)/ml.
After washing three times with PBS, the cover slips were
mounted in DABCO-glycerol/PBS. The cells were visual-
ized under the laser scanning confocal microscope and
analyzed using the Adherent Cell Analysis System (ACAS)
(Meridian Instruments, Okemos, MI).
2.6. Northern blot analysis
For Northern blot analysis THP-1 cells were pretreated
for 2 h with one of the inhibitors prior to stimulation with
PMA (100 ng/ml) for 12 h. At this interval the effect of the
treatment on the cell viability was determined by trypan
blue dye exclusion (Sigma). Cells were lysed by vigorous
vortexing in UltRaspec RNAk (Biotex Laboratories, Inc.,
Houston, TX) at 5106 cells/ml. Total RNA, extracted
according to manufacturer’s instructions, was electrophor-
esed on a 1% agarose gel containing 2.2M formaldehyde.
For each sample 20 Ag of total RNA was loaded on the gel.
RNA was transferred to Hybond N+ membrane (Amersham
Pharmacia Biotech, Inc. Piscataway, NJ) by capillary action.
The membrane was washed, air-dried, and cross-linked
under UV light (Stratalinker UV Crosslinker, Stratagene,
La Jolla, CA). The membrane was prehybridized for 1 h at
65 jC and hybridized overnight at 65 jC with 32P-labeled
probe prepared by random priming. After washing, the
membrane was exposed to a Kodak XAR-5 film, and kept
at 70 jC for exposure. The amount of galectin-3 mRNA
was estimated by densitometric analysis and was expressed
for each sample of treated THP-1 cells as a normalized value
relative to the internal standard (GAPDH or 18S rRNA).
Inhibition was expressed as the percentage of the normal-
ized value in control THP-1 cells treated only with PMA.
Each result represents the average of at least two independ-
ent experiments.2.7. Western blot analysis
The cells were lysed in a lysis buffer (50 mM Tris–HCl,
pH 7.8, 150 mM NaCl, 1% NP40, 0.1% SDS, 1 mM
phenylmethylsulfonyl fluoride). The cell lysate was passed
through a 23-gauge needle to shear chromosomal DNA and
centrifuged at 12,000g for 5 min. The protein concen-
tration in the supernatant was determined with the Bio-Rad
DC Protein Assay kit. Proteins were separated on SDS-
PAGE gels and transferred to polyvinylidine difluoride
membranes (Millipore Corp., Bedford, MA). For each
sample of cells, an equal amount of cell extract containing
20 Ag of total protein was mixed with loading buffer, boiled,
and loaded into the separating gel. Following the transfer,
nonspecific binding sites on the membrane were blocked in
T-TBST (50 mM Tris–HCl, pH 7,4, 150 mM NaCl, 0.1%
Triton X-100) containing 3% BSA. The membrane was
incubated for 2 h with the anti-galectin-3 monoclonal anti-
body M3/38 (1:25 dilution) in T-TBST. After three washes
with T-TBST, the membranes were incubated with horse-
radish peroxidase-conjugated anti-rat IgG (1:8000 dilution).
After three washings, the membranes were incubated with
ECMTL Western blotting detection reagent (Amersham
Pharmacia Biotech). The chemiluminescence signal was
imaged on X-ray film.
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3.1. The role of protein kinases in PMA-induced galectin-3
expression
To study the signaling pathway involved in the regulation
of galectin-3 expression, we used phorbol ester to stimulate
macrophage differentiation of THP-1 cells. Initial experi-
ments have shown that galectin-3 mRNA and protein
increase in a reproducible and time-dependent manner in
PMA-differentiated THP-1 macrophage-like cells. The low
level of galectin-3 transcripts in THP-1 cells increased
significantly as early as 6 h after PMA treatment and
remained at a steady level for the next 48 h (Fig. 1). The
level of galectin-3 protein in THP-1 cells determined by
Western blot analysis (Fig. 2) and flow cytometry (data not
shown) rose significantly 12 h after PMA treatment reaching
more than a twofold increase (228%) at 48 h. The finding
that PMA induces in a reproducible manner a significant
increase in the level of galectin-3 in THP-1 macrophage-like
cells provided a reproducible experimental model to ascer-
tain components of signaling pathways that may be essential
for galectin-3 expression.
Since macrophage differentiation by phorbol esters [32]
involves activation of protein kinase C (PKC), a family of
serine/threonine kinases [33], we investigated the participa-
tion of these enzymes in the regulation of galectin-3
expression. This was carried out by assessing the effects
of protein kinase inhibitors on PMA-induced galectin-3 up-
Fig. 1. The effect of PMA treatment on galectin-3 expression in THP-1
cells. Total RNAwas extracted from THP-1 cells at specified time intervals
after treatment with PMA (100 ng/ml). The RNA was fractionated on a
formaldehyde-containing gel and transferred onto a membrane that was
probed with a 32P-labeled galectin-3 probe and re-probed with a 32P-labeled
GAPDH cDNA probed.
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kinase inhibitor [34] that completely abrogated phorbol ester
induced c-fms expression in THP-1 cells [35], reduced theFig. 2. Western blot analysis of the effect of PMA treatment on galectin-3
expression in THP-1 cells. THP-1 cells were stimulated with PMA (100 ng/
ml) and the level of galectin-3 protein was determined with the M3/38
monoclonal antibody. Panel A: The arrow points to the band of ~31 kDa of
galectin-3 protein. Panel B: Densitometric analysis of each band area
calculated as a percentage of Lane 1 band that is from nontreated THP-1
cells. Lane 2: THP-1 cells treated with the PMA solvent; Lane 3: THP-1
cells treated with PMA for 6 h; Lane 4: THP-1 cells treated with PMA for
12 h; Lane 5: THP-1 cells treated with PMA for 24 h; Lane 6: THP-1 cells
treated with PMA for 48 h.level of PMA-induced galectin-3 mRNA by 81% and the
level of galectin-3 protein in PMA-differentiated THP-1
cells by 51% (Table 1). The reduction by staurosporine of
the PMA-induced signal for up-regulation of galectin-3
expression was an indication that protein kinases play an
important role in up-regulation of galectin-3 gene expres-
sion. However, the lack of specificity of this inhibitor did
not allow for a more specific identification of the signal
pathway involved and prompted us to use more specific
inhibitors of protein kinases. Therefore, we assessed the
effect of calphostin C, a potent and specific inhibitor of PKC
[36], and chelerythrine, claimed to be a potent inhibitor of
PKC [37], on galectin-3 up-regulation in PMA-differenti-
ated THP-1 cells. Calphostin C treatment reduced the level
of PMA-induced galectin-3 transcripts by 60%, but cheler-
ythrine increased the level of galectin-3 mRNA by 25%
(Table 1). Recent reports showing that chelerythrine has no
effect on PKC activity and in fact activates mitogen-acti-
vated protein kinase (MAPK) signaling pathways by pro-
moting JNK1 and p38 activities [38] may explain this result.
Apigenin, a plant flavonoid that inhibits PKC activity by
competing with ATP [39], blocked almost completely (94%)
the induction of galectin-3 mRNA by PMA treatment and
reduced the level of protein by 31% (Table 1). This strong
inhibitory effect may also be the result of apigenin blocking
activation of nuclear transcription factor NF-nB [40]. Treat-
ment with two inhibitors of cAMP-dependent protein kinaseTable 1
The effect of protein kinase inhibitors on the expression of galectin-3 in
PMA-stimulated THP-1 cells
Inhibitor Inhibition
target
Concentration RNA
(%inhibition)
Protein
(%inhibition)
Staurosporine PKC 40 nM 81.5 50.7
Calphostin C PKC 1 AM 59.6 12.3
Chelerythrine PKC? 4 AM – 1.5
Apigenin PKC 25 AM 94.3 30.6
H-89 PKA 15 AM – 0.2
KT5720 PKA 20 AM 4.5 3.8
Genistein PTK 100 AM 90.8 44.2
Tyrphostin A25 PTK 100 AM 17.9 31.6
Tyrphostin A1 None 100 AM 1.6 5.9
PD 098059 MEK1/2 100 AM 86.1 34.3
SB 203580 p38 40 AM 24.2 15.3
The amount of galectin-3 mRNA and protein was estimated in THP-1 cells
pretreated with inhibitors followed by induction with PMA. For mRNA
THP-1 cells were pretreated for 2 h with inhibitors followed by a 12 h
induction with PMA. The amount of galectin-3 mRNA was estimated by
densitometric analysis and was expressed for each sample of treated THP-1
cells as a normalized value relative to the internal standard (GAPDH or 18S
rRNA). Inhibition was expressed as the percentage of the normalized value
in control THP-1 cells treated only with PMA. Each result represents the
average of at least two independent experiments (nz2). For galectin-3
protein THP-1 cells were pretreated for 6 h with inhibitors followed by a
48-h exposure to PMA. The amount of galectin-3 protein was estimated by
densitometric analysis and expressed as normalized values relative to the
level of galectin-3 in the control THP-1 cells treated only with PMA.
Average values from at least two independent experiments are shown
(nz2).
Fig. 3. Activation of the galectin-3 promoter by constitutive expression of
MKK1 or MKK3. RAW264.7 cells were co-transfected with pPG3.5 and
the MKK1 or MKK3 expression plasmids, pMCL-MKK1 N3 or pRC-RSV-
MKK3Glu, or the control vector plasmid pcDNA3. Luciferase activity in
the transfected cells was determined 48 h after transfection. The values were
normalized to h-galactosidase activity and expressed as the percentage of
the normalized value of the luciferase activity in cells co-transfected with
the empty expression vector. The graph is expressed as the meansFS.E. of
at least three independent experiments.
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induced galectin-3 expression at either the mRNA or protein
level (Table 1). These negative results were not unexpected
since phosphorylation of L-plastin and adhesion of leuko-
cytes induced by PMAwere not affected by these inhibitors
[43]. These results demonstrated that inhibitors of PKC
blocked PMA-induced expression of galectin-3 and indi-
cated that selective cyclic nucleotide regulated protein-
serine/threonine kinases are important in signaling PMA
activation of galectin-3 gene expression.
PMA and diacylglycerol have been reported to stimulate
phosphorylation on tyrosine in proteins from monocytes
[44,45] and protein tyrosine kinases were shown to play a
role in the induction by PMA of tissue factor [46] and c-fos
[47]. These findings prompted us to investigate whether
these enzymes were important in the signaling pathway
controlling galectin-3 expression in PMA-differentiated
THP-1 cells. Treatment with genistein, a protein tyrosine
kinase inhibitor that acts by binding to the ATP binding site
[48], lowered the level of galectin-3 transcripts by 91%
while tyrphostin A25, a protein tyrosine kinase inhibitor that
binds to the substrate-binding site [49], reduced the level of
galectin-3 mRNA by 18%. The level of galectin-3 protein
was lowered by 44% and 32%, respectively, by these two
protein kinase inhibitors. No significant reduction was
observed with tyrphostin A1, an inactive form of this type
of inhibitor (Table 1). The difference in the effect of these
two inhibitors may reflect the more specific type of inhib-
ition of the tyrphostins [50]. Overall, these results indicate
that both the serine/threonine kinases and tyrosine kinases
participate in the expression of galectin-3.
Since the activity of MAP kinases was increased by
phorbol ester in monocytic differentiation of myeloid cells
[51] and in macrophages [52], specific MAPK inhibitors
were used to assess the role of these enzymes in galectin-3
expression. PD 098059, a pharmacological inhibitor that
prevents the activation of MEK1/2 [53] and thereby inhibits
phosphorylation of downstream ERK1/2 kinases [54], low-
ered the level of galectin-3 mRNA by 86% and of the
protein by 34%. Addition of SB 203580, an inhibitor of p38
MAPK [54,55], resulted in a 24% reduction in galectin-3
mRNA and 15% reduction in the level of protein (Table 1).
The significant reduction by MAPK and MEK inhibitors of
PMA-induced galectin-3 expression indicates that these
components of the signal transduction pathways have a
significant role to play in PMA-activation of galectin-3
expression.
To further test whether components of the cascade of
MAPK kinases participate in galectin-3 gene expression,
we performed co-transfection studies using constitutively
active MKK1 and MKK3 mutants and galectin-3 promoter.
Co-transfection of the RAW264.7 cells with pPG3.5 and
the constructs pMCL-MKK1 N3 or pRC-RSV-MKK3Glu
raised the activity of galectin-3 promoter, as measured by
the luciferase reporter gene expression, by 185% and
110%, respectively (Fig. 3). Since MEK1/2 has beenshown to activate the ERK1 and ERK2 group of MAP
kinases [56], the response of the galectin-3 promoter to
MKK1 expression suggests a role for these components of
the Ras/MEKK1/MKK1-dependent/AP-1 signal transduc-
tion pathway in PMA-induced up-regulation of galectin-3
expression in macrophages. The activation of galectin-3
promoter by MKK3 and the inhibitory effect of SB 280305
indicate that the p38 MAPK signal transducing pathway
may also participate in PMA induction of galectin-3 up-
regulation.
3.2. Galectin-3 promoter activation by Ras and Jun
The blocking of galectin-3 expression by MAPKs
inhibitors and the stimulation of the galectin-3 promoter
activity by MKK1 and MKK3 prompted us to investigate
whether Ras, a GTP-binding switch protein that regulates a
signaling cascade of kinases [57], may be involved in
signaling galectin-3 expression in macrophages. When
RAW264.7 cells were co-transfected with Ha-Ras expres-
sion vector along with pPG3.5, a plasmid vector containing
the rabbit galectin-3 promoter region, co-expression of Ha-
Ras stimulated galectin-3 promoter activity 10-fold com-
pared with vector-transfected controls (Fig. 4). This result
Fig. 4. Activation of the galectin-3 promoter by Jun and Ras. RAW264.7
cells were co-transfected with pPG3.5 and either pRSVneo, pRSV-c-jun,
pSV-v-jun, or pRSV-r161. After 48 h the transfected cells were lysed and
the luciferase activity of the cell lysates was assayed and normalized to h-
galactosidase activity. The luciferase activity of cells transfected with
pRSVneo was considered as the reference standard. The luciferase activity
of cells transfected with expression plasmids for c-Jun, v-Jun, or Ha-ras
was expressed as a percentage of cells transfected with pRSVneo. The
values represent the meansFS.E. of at least three independent experiments.
Fig. 5. Simplified map of plasmid pPG3.5 and deletion mutants modified
after [13]. The three AP-1 sites identified within the rabbit galectin-3
promoter were deleted in PG3dE and pPG3dG but SP1 sites were still
present [13].
Fig. 6. Western blot analysis of the effect of Jun and Ras on the galectin-3
expression. THP-1 cells were transfected with either pRSVneo, pRSV-c-
jun, pSV-v-jun, or pRSV-r161. After 48 h the cells were lysed and the
amount of galectin-3 was measured by Western blot analysis. Densitometry
analysis of the blots expressed in arbitrary units was referred to pRSVneo
transfected cells taken as reference standard. The values represent the
meansFS.E. of at least three independent experiments.
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regulated by signal transduction pathways linked to acti-
vated Ras.
Since our results showed that PMA induces galectin-3
expression in macrophages, it was considered of interest to
investigate the response of galectin-3 to Jun, an AP-1
protein that have an established role in the PMA-induced
gene expression [58]. Cotransfections of pPG3.5 and the
expression vectors pRSV-c-Jun or pSV-v-Jun were carried
out in RAW264.7 cells. Expression of the protooncogene c-
Jun enhanced the galectin-3 promoter activity by more than
threefold compared to the activity induced by the pRSVneo
construct, while expression of v-Jun raised the level of
galectin-3 promoter activity by more than fourfold (Fig. 4).
Because the sequence of 2097 bp of the 5V-flanking
region of the rabbit galectin-3 exon 1 contained several
putative binding sites for AP-1 and AP-2 [13] that could
explain the stimulation of the promoter activity by Jun, we
carried out co-transfections of c-Jun with pPG3dE and
pPG3dG, two deletion mutants of the rabbit galectin-3
promoter region (Fig. 5). Co-transfection of c-Jun with
pPG3dE, which has all of the 5V upstream region deleted
except the last 127 bp upstream from the P1 transcription
site, resulted in a reduction of the galectin-3 promoter
activity by almost 50%. In co-transfections of c-Jun with
pPG3dG that had the deletion extended to position +42 in
relation to the P1 site, only 20% of the galectin-3 promoter
activity was attained. It may be interesting to note that the
deleted 5Vupstream region in pPG3dE included three AP-1
sites and two AP-2 sites whereas at least nine Sp1 sites
were maintained in the vicinity of the P1 [13]. In pPG3dGall these sites except one were deleted. These results
indicate that the AP-1 factor has an important, but probably
not unique, function in the transcriptional activity of
galectin-3 promoter.
In order to further assess the response of galectin-3 to
Ras and Jun, PMA-differentiated THP-1 cells were trans-
fected with the dominant expression vectors for Ha-Ras, c-
Jun, and v-Jun, and the expression of galectin-3 in the
transfected cells was measured by Western blot analysis. In
cells transfected with the v-Jun oncogene galectin-3 protein
increased by 71F2% over cells transfected with the neo
expressing vector. Cells transfected with Ha-Ras expressed
55F2% more galectin-3 protein whereas in cells transfected
with c-Jun the level of galectin-3 increased by 19F6% as
compared to cells transfected with the neo gene (Fig. 6).
These results seem to confirm that Jun and Ras play a
significant role in the expression of galectin-3 in macro-
phages.
Fig. 7. Immunofluorescence staining for galectin-3 in resident peritoneal
macrophages after exposure to modified lipoproteins. Resident peritoneal
macrophages were cultured in RPMI 1640 medium supplemented with 4%
LPDS and treated with: (A) AcBSA (50 Ag/ml); (B) OxLDL (50 Ag/ml);
(C) AcLDL (50 Ag/ml). After 4 days of treatment, the cells were fixed and
stained with the anti-galectin-3 M3/38 monoclonal antibody followed by
FITC-conjugated anti-rat IgG secondary antibody. Specimens were
examined by fluorescence confocal microscopy.
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The abundant presence of galectin-3 in foam cells from
atherosclerotic lesions [18] and the demonstration that
modified lipoproteins activate components of the MAPK
signaling pathway [59–62] and stimulate phospholipase D
activity resulting in production of diacylglycerol [63]
prompted us to study the effect of modified lipoproteins on
galectin-3 expression in macrophages. To examine whether
the expression of galectin-3 is modulated by modified lip-
oproteins, macrophages were exposed to AcLDL or OxLDL.
Changes in the expression of galectin-3 protein and mRNA
were assessed in parallel with the amount of intracellular
lipid accumulation. Numerous yellow fluorescent lipid drop-
lets stained with Nile red were visualized by confocal
microscopy in the cytoplasm of macrophages cultured with
OxLDL or AcLDL and very little intracellular lipid was seen
in macrophages cultured in medium supplemented with
LPDS (data not shown). Duplicate cultures of resident
peritoneal macrophages exposed to OxLDL (50 Ag/ml) or
AcLDL (50 Ag/ml) for 4 days were immunostained for
galectin-3. Intense positive staining was detected by con-
focal microscopy in the enlarged lipid-laden macrophages
labeled with anti-galectin-3 monoclonal antibody (Fig. 7).
The distribution of the galectin-3 immunofluorescent stain-
ing measured by the ACAS 570 showed that galectin-3
immunofluorescence was significantly increased in lipid-
laden cells after treatment with OxLDL or AcLDL compared
to that of macrophages cultured in medium supplemented
with LPDS (Fig. 8). Macrophages treated with AcLDL
showed a normal distribution of the fluorescence intensity
with an average of 1302 units, while macrophages incubated
with OxLDL showed an average of 930 units with a bimodal
distribution showing two peaks, one around 700 and another
at 1000 units. Macrophages cultured in LPDS-supplemented
medium for 4 days showed an average of 762 units with a
bimodal distribution of the fluorescence intensity, with one
peak around 500 units and another close to 1000 units. The
increase in the fluorescence intensity generated by galectin-3
immunostaining in the peritoneal macrophages loaded with
lipids after treatment with modified lipoproteins was statisti-
cally significant (P<0.0001) but the average values and the
type of distribution were different in macrophages exposed
to AcLDL versus macrophages exposed to OxLDL, suggest-
ing the possibility of different subsets in the population of
resident peritoneal macrophages.
The amount of galectin-3 in peritoneal macrophages
incubated for 4 days with AcLDL assessed by Western blot
analysis was 31% higher than in control macrophages cul-
tured in medium alone. The level of galectin-3 protein in
macrophages incubated with OxLDL for the same length of
time was 51% higher than that seen in control macrophages
(Fig. 9). The effect of modified lipoproteins on the level of
galectin-3 mRNAwas assessed by Northern blot analysis in
mouse resident peritoneal macrophages cultured in the pres-
K. Kim et al. / Biochimica et Bence of AcLDL or AcBSA for 2 days. Each blot was probed
with a cDNA probe for galectin-3 RNA and re-probed with a
probe for 18S RNA and the change in galectin-3 mRNAwas
Fig. 8. Cellular distribution of galectin-3 in resident peritoneal macrophages after exposure to modified lipoproteins. Resident peritoneal macrophages were
cultured in RPMI 1640 medium supplemented with 4% LPDS and treated with: (A) AcLDL (50 Ag/ml) or (B) OxLDL (50 Ag/ml). After 4 days of treatment,
the cells were fixed and stained with the anti-galectin-3 M3/38 monoclonal antibody followed by FITC-conjugated anti-rat IgG secondary antibody. A
minimum of 200 cells per sample was analyzed using the Meridian Adherent Cell Analysis System. The black area shows the distribution of fluorescence in
cells loaded with AcLDL (panel A) or OxLDL (panel B), the dark-gray area shows the fluorescence values of control cells, and the light gray area represents
the overlapping cell population from treated samples and their controls.
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Compared to the macrophages treated with AcBSA, macro-
phages incubated with AcLDL showed a 28% increase in the
galectin-3/18S RNA ratio (data not shown). These results
demonstrate that significant overexpression of galectin-3Fig. 9. Western blot analysis of the effect of exposure to modified
lipoproteins on the expression of galectin-3 in macrophages. Murine
resident peritoneal macrophages were cultured in medium RPMI 1640 and
incubated with: Lane 1: culture medium; lane 2: AcLDL (50 Ag/ml); lane 3:
OxLDL (50 Ag/ml). The level of cellular galectin-3 was determined after 4
days of treatment by Western blot analysis. The cells were lysed in the
extraction buffer and extracted proteins were separated by gel electro-
phoresis, transferred to a PVDF membrane, and stained with the anti-
galectin-3 M3/38 monoclonal antibody followed by peroxidase-conjugated
anti-rat IgG complex. The band of e¨32kDa is galectin-3 identified with the
monoclonal antibody M3/38.occurs following exposure of resident peritoneal macro-
phages to modified lipoproteins.4. Discussion
In order to identify components of signal transduction
pathways that may be involved in the regulation of galectin-
3 expression, we applied the experimental model of phorbol
ester induction of macrophage differentiation. Phorbol esters
have been shown to increase galectin-3 protein and mRNA
levels in human promyelocytic HL-60 cells [7,8] and to
stimulate the activity of the galectin-3 promoter [13]. Since
most of the biological effects of phorbol esters are thought
to occur as a result of their ability to substitute for diac-
ylglycerol and activate PKC [15], it seems reasonable to
expect that PMA-induction of macrophage differentiation
may provide useful information on the signaling involved in
the regulation of galectin-3 expression. Our work has
demonstrated that PMA-stimulation of galectin-3 expression
was inhibited by the PKC inhibitors staurosporine, calphos-
tin C, and apigenin, and by the MEK1 inhibitor PD 098059.
Furthermore, significant activation of the galectin-3 pro-
moter was observed by co-transfection with Ha-Ras and
MKK1 (MAPKK, MEK1), an activator of p42/44 MAPK
[64]. Although not conclusive, these results point to the
involvement of the PKC-Ras-Raf-MKK1 pathway in PMA-
stimulated galectin-3 gene expression in macrophages. The
blocking effect on galectin-3 expression by protein tyrosine
kinase inhibitors tyrphostin A25 and genistein, and by SB
203580, a specific inhibitor of p38 MAPK, indicates the
K. Kim et al. / Biochimica et Biophysica Acta 1641 (2003) 13–23 21involvement of other components of the signaling pathways.
The finding that expression of MKK3, a specific activator of
p38 MAPK [29], enhanced galectin-3 promoter activity
suggests the involvement of the PKC-Ras-Raf-MKK1-
MKK3-p38 pathway in galectin-3 gene expression in mac-
rophages.
Phorbol esters are known to stimulate the promoters of
several cellular genes that share the cis-acting 12-O-
tetradecanoyl-phorbol-13-acetate (TPA) response element
(TRE) 5V-TGANTCAA-3V [65], which serves as a binding
site for the transcription factor AP-1 [66]. We examined
the response of the galectin-3 promoter in the presence of
overexpressed Jun protein and found that both c-Jun and
v-Jun increased significantly the activity of this promoter.
Moreover, expression of Jun resulted in overexpression of
galectin-3 in PMA-stimulated THP-1 macrophages. These
findings suggest a role for the AP-1 complex in the
transcriptional activation of galectin-3 gene. Multiple
AP-1 sites were identified in the 5V-flanking region of
human [10] and rabbit galectin-3 gene, and a significant
decrease in activity was noticed after deletion of these
sites [13]. Moreover, antisense-Jun oligonucleotides
reduced the expression of galectin-3 in glioblastoma cells
exposed to ultraviolet light (UV) [67]. The increase in
galectin-3 promoter activity induced by Jun suggests that
activation of AP-1 transcriptional factor may occur as a
result of PMA-activated Ras-dependent/AP-1 signal trans-
duction pathway and is one of the components that plays
an important role in the regulation of galectin-3 gene
expression. The strong inhibitory effect on galectin-3
expression by apigenin, which in addition of being a
PKC inhibitor is an inhibitor of the nuclear factor NF-nB
activation [40], suggests a more complex regulation of
this gene. The presence of two putative NF-nB binding
sites in the human galectin-3 gene promoter [10] and the
inhibition of galectin-3 UV-induction by a specific pro-
teasome inhibitor that blocks transcriptional activation
through NF-nB [67] lend support to this assumption.
This work has demonstrated that the level of galectin-3
increased dramatically as mouse resident peritoneal macro-
phages in vitro accumulated lipids and became foam cells
after treatment with modified lipoproteins. Both in advanced
and early human atherosclerotic changes galectin-3 immu-
nostaining prevailed in the foam cells that are frequently
cellular components of these lesions [18]. Overexpression of
different molecules in macrophage-derived foam cells of
atherosclerotic lesions has been amply documented [68].
The activated macrophages that transform into foam cells
via uptake of modified lipoproteins express receptors MSR-
A and CD36 that mediate the high affinity binding and
internalization of modified lipoproteins [20,21] and produce
inflammatory mediators and effectors such as interleukin-1h
[22], interleukin-1h [23], and urokinase-type plasminogen
activator [24]. The higher level of galectin-3 transcripts and
protein found in mouse resident peritoneal macrophages
loaded with lipids following exposure to modified lipopro-teins indicates that galectin-3 is joining this group of
molecules overexpressed in foamy macrophages.
Overexpression of galectin-3 in macrophages exposed to
modified lipoproteins and recent reports indicating that
galectin-3 plays an active role in the endocytosis of
advanced glycation end products (AGE) [69] and modified
lipoproteins [70], and is up-regulated in renal tissue of
diabetic rats [71], suggest that this protein is an important
participant in the development of atherosclerotic lesions. It
is noticeable that p38 MAPK is a key downstream effector
of RAGE, another receptor for AGE that activates NF-nB
[72] and signals a proinflammatory phenotypic change.
Since galectin-3 plays a definite role in inflammation [73]
its up-regulation following lipid accumulation involving this
signaling pathway suggests an important role in the devel-
opment of atherosclerotic lesions. If this assumption proves
to be correct, understanding the mechanisms that control the
expression of this protein becomes significant in providing
means to control atherogenesis.Acknowledgements
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